MedTrace Logo

Observational Study on the Effect of Switch to Lurasidone in Subjects With Schizophrenia"

NCT04312503 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 95

Last updated 2023-05-06

No results posted yet for this study

Summary

The aim of this study is observation, in an Italian real-world setting, of metabolic effects in patients with schizophrenia who will switch from any mono-therapy or poly-therapy antipsychotic regimen to monotherapy with lurasidone or to one of the other four most used atypical antipsychotics.

Conditions

Interventions

DRUG

Lurasidone

Patients are treated with dosages according clinical practice

DRUG

aripiprazole, olanzapine, quetiapine or risperidone

Patients are treated with dosages according clinical practice

Sponsors & Collaborators

  • Aziende Chimiche Riunite Angelini Francesco S.p.A

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-13
Primary Completion
2022-10-31
Completion
2022-10-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04312503 on ClinicalTrials.gov